MX2017000208A - Derivados de quinolizinona como inhibidores de pi3k. - Google Patents

Derivados de quinolizinona como inhibidores de pi3k.

Info

Publication number
MX2017000208A
MX2017000208A MX2017000208A MX2017000208A MX2017000208A MX 2017000208 A MX2017000208 A MX 2017000208A MX 2017000208 A MX2017000208 A MX 2017000208A MX 2017000208 A MX2017000208 A MX 2017000208A MX 2017000208 A MX2017000208 A MX 2017000208A
Authority
MX
Mexico
Prior art keywords
pi3k inhibitors
quinolizinone derivatives
quinolizinone
derivatives
tautomer
Prior art date
Application number
MX2017000208A
Other languages
English (en)
Inventor
Sanjeev Anant Kulkarni
Manojkumar Ramprasad Shukla
Venkata P Palle
Rajender Kumar Kamboj
Kumar Jana Nirmal
Jaysing Mahangare Sachin
Popatrao Vidhate Prashant
Raychand Lagad Dipak
Jagannath Tarage Anand
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53716533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017000208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2017000208A publication Critical patent/MX2017000208A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se divulgan compuestos de la fórmula I, sus formas tautoméricas, estereoisómeros y sales farmacéuticamente aceptables de los mismos, en donde R1-R4 y n son como se define en la descripción, las composiciones farmacéuticas incluyen un compuesto, tautómero, estereoisómero o sal del mismo, y métodos para el tratamiento o prevención de enfermedades o trastornos, por ejemplo, cáncer, que son susceptibles de tratamiento o prevención inhibiendo la enzima PI3K de un sujeto.
MX2017000208A 2014-07-04 2015-07-01 Derivados de quinolizinona como inhibidores de pi3k. MX2017000208A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2182MU2014 2014-07-04
PCT/IB2015/054958 WO2016001855A1 (en) 2014-07-04 2015-07-01 Quinolizinone derivatives as pi3k inhibitors

Publications (1)

Publication Number Publication Date
MX2017000208A true MX2017000208A (es) 2017-05-01

Family

ID=53716533

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000208A MX2017000208A (es) 2014-07-04 2015-07-01 Derivados de quinolizinona como inhibidores de pi3k.

Country Status (25)

Country Link
US (1) US9944639B2 (es)
EP (1) EP3164400A1 (es)
JP (1) JP6291601B2 (es)
KR (1) KR20170082490A (es)
CN (1) CN106470996B (es)
AP (1) AP2016009661A0 (es)
AU (1) AU2015283671B2 (es)
BR (1) BR112017000132A2 (es)
CA (1) CA2954231A1 (es)
CL (1) CL2017000006A1 (es)
CO (1) CO2017000011A2 (es)
CR (1) CR20160600A (es)
CU (1) CU24428B1 (es)
EA (1) EA201692557A1 (es)
GE (1) GEP20186934B (es)
HK (1) HK1232227A1 (es)
IL (1) IL249674B (es)
MA (1) MA40250A (es)
MX (1) MX2017000208A (es)
PE (1) PE20170640A1 (es)
PH (1) PH12017500007A1 (es)
SG (1) SG11201610770PA (es)
SV (1) SV2017005354A (es)
UA (1) UA115296C2 (es)
WO (1) WO2016001855A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10328060B2 (en) * 2014-11-01 2019-06-25 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2017103825A1 (en) 2015-12-18 2017-06-22 Lupin Limited Quinolizinone derivatives as pi3k inhibitors
CA3083040A1 (en) 2018-01-20 2019-07-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
EP3828184A4 (en) * 2018-08-21 2022-05-04 Medshine Discovery Inc. PYRAZOLOPYRIMIDI DERIVATIVES AND USE THEREOF AS A PI3K INHIBITOR
KR20220004105A (ko) * 2019-04-23 2022-01-11 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
WO2021164789A1 (zh) * 2020-02-21 2021-08-26 南京明德新药研发有限公司 一种吡唑并嘧啶类化合物的晶型及其应用
CR20240045A (es) * 2021-08-09 2024-02-20 Scorpion Therapeutics Inc Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO2001081346A2 (en) 2000-04-25 2001-11-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
US20050239809A1 (en) 2004-01-08 2005-10-27 Watts Stephanie W Methods for treating and preventing hypertension and hypertension-related disorders
CA2566436C (en) 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
CN101031569B (zh) 2004-05-13 2011-06-22 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
JP2008500338A (ja) 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
CA2569406A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
CA2598409A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
MX2008012929A (es) 2006-04-04 2008-12-17 Univ California Antagonistas de cinasa.
US20100216820A1 (en) 2006-11-13 2010-08-26 White Stephen L Thienopyrimidiones for treatment of inflammatory disorders and cancers
NZ579834A (en) 2007-03-23 2012-03-30 Amgen Inc Heterocyclic compounds as selective inhibitors of PI3K activity
SI2139882T1 (sl) 2007-03-23 2014-03-31 Amgen Inc. 3-substituirani kinolinski ali kinoksalinski derivati in njihoba uporaba kot inhibitorji fosfatidilinozitol 3-kinaze (pi3k)
CA2680783C (en) 2007-03-23 2012-04-24 Amgen Inc. Heterocyclic compounds and their uses
GEP20125635B (en) 2007-11-13 2012-09-10 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
SG187425A1 (en) 2008-01-04 2013-02-28 Intellikine Llc Certain chemical entities, compositions and methods
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US8440677B2 (en) 2009-03-24 2013-05-14 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
AU2010239312A1 (en) 2009-04-20 2011-11-10 Gilead Calistoga Llc Methods of treatment for solid tumors
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
SG176986A1 (en) 2009-06-25 2012-02-28 Amgen Inc Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
EP2445898A2 (en) * 2009-06-25 2012-05-02 Amgen, Inc 4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors
JP2012531438A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 複素環式化合物およびその使用
MY162507A (en) * 2009-06-29 2017-06-15 Incyte Holdings Corp Pyrimidinones as pi3k inhibitors
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
AP2012006294A0 (en) 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
WO2011058112A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrazole derivatives as kinase inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
MX2012006953A (es) 2009-12-18 2012-10-09 Amgen Inc Compuestos heterociclicos y sus usos.
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2011156759A1 (en) 2010-06-11 2011-12-15 Calistoga Pharmaceuticals, Inc. Methods of treating hematological disorders with quinazolinone compounds in selected patients
US8686137B2 (en) 2010-06-30 2014-04-01 Amgen Inc. Heterocyclic compounds and their uses
CA2803620A1 (en) 2010-06-30 2012-01-05 Amgen Inc. Heterocyclic compounds and their uses
ES2472720T3 (es) 2010-07-01 2014-07-02 Amgen Inc. Compuestos heteroc�clicos y su uso como inhibidores de actividad PI3K
AU2011272853A1 (en) 2010-07-01 2013-01-10 Amgen Inc. Heterocyclic compounds and their use as inhibitors of PI3K activity
WO2012003271A1 (en) 2010-07-02 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
WO2012040634A1 (en) 2010-09-24 2012-03-29 Gilead Calistoga Llc Atropisomers of pi3k-inhibiting compounds
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
AU2011323243A1 (en) 2010-11-04 2013-05-23 Amgen Inc. Heterocyclic compounds and their uses
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
US8765768B2 (en) 2010-11-17 2014-07-01 Amgen Inc. Heterocyclic compounds and their uses
AU2011349669A1 (en) 2010-12-23 2013-07-11 Amgen Inc. Heterocyclic compounds and their uses
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
EP2683377A1 (en) 2011-03-11 2014-01-15 Gilead Calistoga LLC Combination therapies for hematologic malignancies
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
AU2012249500A1 (en) * 2011-04-29 2013-11-28 Exelixis, Inc. Method of treating lymphoma using pyridopyrimidinone inhibitors of PI3K/MTOR
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
CN102838601A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 选择性磷酰肌醇3-激酶δ抑制剂
CN102838600A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
RU2014111823A (ru) 2011-08-29 2015-10-10 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
WO2013052699A2 (en) 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
WO2013082540A1 (en) 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
TWI586378B (zh) 2012-03-13 2017-06-11 瑞斯比維特有限公司 新穎醫藥調配物
ME02473B (me) 2012-04-04 2017-02-20 Amgen Inc Heterociklična jedinjenja i njihova primjena
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
ES2647416T3 (es) 2012-07-04 2017-12-21 Rhizen Pharmaceuticals S.A. Inhibidores de PI3K delta selectivos
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
CN104768952B (zh) 2012-08-08 2016-10-19 山东亨利医药科技有限责任公司 PI3Kδ抑制剂
US20140051696A1 (en) 2012-08-14 2014-02-20 Gilead Calistoga Llc Therapies for treating cancer
US9388189B2 (en) 2012-10-16 2016-07-12 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
MX2020009849A (es) 2012-11-01 2021-09-13 Infinity Pharmaceuticals Inc Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa.
US20140120060A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
CA2895782C (en) 2012-12-21 2017-08-22 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
NZ708870A (en) 2012-12-21 2016-09-30 Gilead Calistoga Llc Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
WO2014106800A2 (en) 2013-01-04 2014-07-10 Aurigene Discovery Technologies Limited Substituted 2-amino pyrimidine derivatives as kinase inhibitors
UY35332A (es) 2013-02-15 2014-11-28 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
US9216985B2 (en) 2013-03-28 2015-12-22 Scifluor Life Sciences, Inc. 3-aryl-2-((arylamino)methyl)quinazolin-4-(3H)-ones
EA028319B1 (ru) 2013-06-14 2017-11-30 Джилид Калистога Ллс Ингибиторы фосфатидилинозитол-3-киназы
CN111153905A (zh) 2013-07-02 2020-05-15 理森制药股份公司 PI3K蛋白激酶抑制剂，特别是δ抑制剂和/或γ抑制剂
CN104418849B (zh) 2013-09-02 2020-04-21 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
MX2016003456A (es) 2013-09-22 2017-05-25 Calitor Sciences Llc Compuestos aminopirimidina sustituidos y metodos de uso.
MX2016012021A (es) 2014-03-19 2017-04-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
CN105130966B (zh) 2014-05-07 2019-05-24 广东东阳光药业有限公司 炔基化合物及其使用方法和用途
WO2015175579A1 (en) 2014-05-15 2015-11-19 Calitor Sciences, Llc Alkynyl compounds and methods of use
ES2833025T3 (es) 2014-06-13 2021-06-14 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa
KR20170010063A (ko) 2014-06-13 2017-01-25 길리애드 사이언시즈, 인코포레이티드 포스파티딜이노시톨 3-키나제 억제제
BR112016028642A2 (pt) 2014-06-13 2017-08-22 Gilead Sciences Inc composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo.
JP6391718B2 (ja) 2014-06-24 2018-09-19 ギリアード サイエンシーズ， インコーポレイテッド ホスファチジルイノシトール３−キナーゼ阻害剤
US10328060B2 (en) * 2014-11-01 2019-06-25 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
CN105130984B (zh) 2015-09-23 2017-03-29 前湾医药科技（深圳）有限公司 一种咪唑并吡啶类化合物与在制备pi3k抑制剂中的应用

Also Published As

Publication number Publication date
BR112017000132A2 (pt) 2018-01-09
HK1232227A1 (zh) 2018-01-05
IL249674A0 (en) 2017-02-28
EA201692557A1 (ru) 2017-05-31
WO2016001855A1 (en) 2016-01-07
CN106470996B (zh) 2019-02-22
IL249674B (en) 2019-06-30
GEP20186934B (en) 2018-12-10
PH12017500007A1 (en) 2017-05-15
CU20160195A7 (es) 2017-05-10
CO2017000011A2 (es) 2017-04-10
AU2015283671A1 (en) 2017-02-02
CU24428B1 (es) 2019-06-04
UA115296C2 (uk) 2017-10-10
AU2015283671B2 (en) 2018-07-05
CR20160600A (es) 2017-03-07
KR20170082490A (ko) 2017-07-14
CA2954231A1 (en) 2016-01-07
JP6291601B2 (ja) 2018-03-14
JP2017519786A (ja) 2017-07-20
SV2017005354A (es) 2018-10-05
AP2016009661A0 (en) 2016-12-31
US20170137421A1 (en) 2017-05-18
CN106470996A (zh) 2017-03-01
SG11201610770PA (en) 2017-01-27
PE20170640A1 (es) 2017-05-26
CL2017000006A1 (es) 2017-06-02
US9944639B2 (en) 2018-04-17
MA40250A (fr) 2017-05-10
EP3164400A1 (en) 2017-05-10

Similar Documents

Publication Publication Date Title
PH12018500360A1 (en) Heteroaryl derivatives as parp inhibitors
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MX2023001876A (es) Derivados de rapamicina.
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12018550120A1 (en) Steroid derivative fxr agonist
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
PH12017500007A1 (en) Quinolizinone derivatives as p13k inhibitors
PH12019500480A1 (en) Pyridine compound
MX2021009378A (es) Derivados de pirazolopirimidina como inhibidor de cinasa.
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
NZ727185A (en) Phosphatidylinositol 3-kinase inhibitors
MY197698A (en) Oxysterols and methods of use thereof
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
IN2015MN00002A (es)
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
NZ726695A (en) Gls1 inhibitors for treating disease
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
MY192305A (en) Bipyrazole derivatives as jak inhibitors